What Is Bimatoprost for Eyelashes?
Plain answer: Bimatoprost is a prescription prostaglandin analogue. LATISSE contains bimatoprost 0.03% and is approved to treat thin or inadequate eyelashes. Human trials show it can increase lash length, thickness, and darkness. The drug label also lists eye and eyelid risks. Its results and warnings belong to this exact drug and use.
Review status: This is a source-checked editorial draft. Qualified review required before indexation. An ophthalmologist or optometrist must review ocular and drug claims. A dermatologist or cosmetic toxicology expert must review claims within their scope.
Quick facts
| Drug | LATISSE, bimatoprost ophthalmic solution 0.03%. |
|---|---|
| U.S. status | Human prescription drug under a New Drug Application. |
| Indication | Eyelash hypotrichosis, by increasing growth including length, thickness, and darkness. |
| Application in label | Once nightly on the skin of the upper eyelid margin with a sterile applicator. Not on the lower lash line. |
| Effectiveness evidence grade | A for the exact prescription use. |
| Label check | DailyMed label revised July 2024; checked 2026-07-11. |
Does bimatoprost grow eyelashes?
Yes, when discussing the exact prescription product and labeled use. The current LATISSE label states that bimatoprost 0.03% treats eyelash hypotrichosis by increasing growth, including length, thickness, and darkness.
The label describes a multicenter, double-masked, randomized, vehicle-controlled study with 278 adults treated for four months. This is much stronger evidence than a testimonial, a brand consumer survey, or a study of a different cosmetic formula.
At week 16, 107 of 137 people using LATISSE, or 78%, improved by at least one grade on the label's eyelash scale. The vehicle group result was 26 of 141 people, or 18%. These results belong to LATISSE 0.03% used under the study conditions.
More applications do not increase growth according to the label. After stopping, eyelash appearance is expected to return toward its earlier level.
Effectiveness evidence
The Lash List editorial grade key: A = strong controlled human evidence for the exact use. B = one controlled human study. C = a small uncontrolled human formula study. D = laboratory, animal, scalp-hair, or supplier evidence. E = label presence, theory, or no direct human eyelash evidence. This is our editorial rubric, not a recognized clinical grading system. Grades do not rate safety.
| Claim | Evidence grade | Boundary |
|---|---|---|
| LATISSE 0.03% increases eyelash growth for hypotrichosis. | A | Supported for the prescription product, labeled strength, route, and indication. |
| A cosmetic serum with another prostaglandin analogue will perform the same way. | E | Not supported by the bimatoprost label. |
| A peptide serum is equivalent to bimatoprost. | E without a direct comparison trial | Do not claim equivalence from separate studies or marketing timelines. |
Safety assessment
| Assessment status | Assessed under prescription-label conditions with known warnings, precautions, and adverse reactions. |
|---|---|
| Authority | Current U.S. prescribing information on DailyMed. |
| Scope | Bimatoprost ophthalmic solution 0.03% applied as directed to the upper eyelid margin. |
| Jurisdiction | United States prescription drug label. |
| Known effects | Eye itching, conjunctival redness, skin hyperpigmentation, ocular irritation, dry-eye symptoms, periorbital redness, iris pigmentation, and postmarketing reports including periorbital fat atrophy. |
| Data gaps | Pregnancy data are not based on adequate and well-controlled studies in pregnant women. Postmarketing event frequencies often cannot be estimated. |
| Checked date | 2026-07-11 |
Which side effects appear in the drug label?
The most common reactions in the four-month clinical trial occurred in about 3% to 4% of participants. They were eye itching, conjunctival hyperemia, and skin hyperpigmentation. Other trial reactions occurred in fewer than 4% and included ocular irritation, dry-eye symptoms, and periorbital redness.
The label warns that increased brown iris pigmentation may occur and is likely to be permanent. Eyelid and nearby skin darkening has usually been reported as reversible after stopping. These are not the same outcome.
Postmarketing reports include periorbital and eyelid changes associated with fat atrophy, deepening of the eyelid sulcus, and eyelid ptosis. Because these are voluntary reports, the label says frequency and causation may not be reliably established.
Who needs extra clinical guidance?
- People using bimatoprost or another prostaglandin analogue to lower eye pressure.
- People with active intraocular inflammation or risk factors for macular edema.
- People who are pregnant, nursing, or planning pregnancy.
- People with contact lenses, because the label gives specific removal and reinsertion instructions.
This page cannot decide whether the medicine is right for an individual. A prescriber can review eye history, other medicines, and the label.
Is bimatoprost a cosmetic ingredient?
LATISSE is a prescription drug, not an ordinary cosmetic lash serum. The FDA explains that cosmetics generally are not pre-approved, while products intended to treat a condition or affect body structure can be drugs. A cosmetic analogue does not become FDA-approved because it sounds similar to bimatoprost.
How is it different from isopropyl cloprostenate?
They are different chemicals. Bimatoprost has a specific prescription indication and controlled human evidence. Isopropyl cloprostenate appears in some cosmetic labels and has a different regulatory and evidence record. Do not transfer trial percentages, approval, or dosage between them.
Sources and evidence limits
- LATISSE prescribing information on DailyMed, revised July 2024.
- FDA authority over cosmetics, used only to explain the drug-cosmetic boundary.
- 2024 peer-reviewed eyelash serum review, used as secondary clinical context.
Product label example
The current LATISSE drug label identifies bimatoprost as its active ingredient. That evidence belongs to the labeled prescription product and use. Source checked July 11, 2026.
Related ingredient pages
Use the evidence system
Return to the lash serum ingredient hub, paste a current ingredient label into the checker, or read the ingredient risk guide.
This page is educational. It does not diagnose an eye condition or replace advice from a qualified clinician.